The Conversation (0)
OncBioMune Pharmaceuticals announced the protocol for their planned Phase II study of ProscaVax treating prostate cancer is being reviewed by the respective regulatory committee.
OncBioMune Pharmaceuticals (OTCQB:OBMP) announced the protocol for their planned Phase II study of ProscaVax treating prostate cancer is being reviewed by the respective regulatory committee.
As quoted in the press release:
In the trial, ProscaVax, OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of tumor-associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF), will be evaluated for safety, tolerability and efficacy in treatment-naïve prostate cancer patients at disease presentation. Per the protocol, patients to be enrolled in the study will be newly diagnosed with prostate cancer, deciding in collaboration with their oncologist to forego standard approved therapies, such as a radical prostatectomy, radiation or brachytherapy, in favor of careful monitoring for disease progression, a process known more commonly as “active surveillance.” Presently, there are no FDA-approved treatments for prostate cancer patients in active surveillance.
“The Regulatory Committee is a component of the Institutional Review Board and integral to the protocol approval process to commence the study,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “I interpret the protocol now being in their hands as a signal that we are getting close to conducting the first ever trial of ProscaVax as a front-line treatment for prostate cancer.”
Click here to read the full press release.
Source: www.marketwired.com
